Natera Inc Stock Price, News & Analysis

Natera has published a clinical experience study showcasing its Panorama SNP-based noninvasive prenatal test (NIPT) for twin pregnancies, with findings based on 18,984 cases over 27 months. The study demonstrated a positive predictive value (PPV) of 88.7% for trisomy 21 screening, reaching 90.4% when including suggestive findings. Unique to Panorama is its ability to determine zygosity. The study corroborates earlier findings that aneuploidy rates are higher in dizygotic twins. Natera emphasizes its commitment to generating real-world evidence to enhance prenatal care.

Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA testing, will participate in the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022, at 12:00 p.m. PT (3:00 p.m. ET). CEO Steve Chapman and CFO Mike Brophy will present at the event held at the Lotte New York Palace. A live webcast of the presentation will be accessible on the Natera Investor Relations website and archived for future reference.

Natera, Inc. (Nasdaq: NTRA) announced the pricing of its underwritten public offering of 11,430,000 shares of common stock at $35.00 per share. The offering is expected to close on November 18, 2022, subject to customary conditions. Additionally, Natera has granted underwriters a 30-day option to purchase up to 1,714,500 additional shares. Morgan Stanley, Cowen, and SVB Securities are managing the offering, which is filed under an effective shelf registration statement with the SEC. This issuance aims to support Natera's ongoing operations in cell-free DNA testing for oncology and women's health.

Natera, Inc. (Nasdaq: NTRA), based in Austin, Texas, has announced a proposed follow-on public offering of $350 million in common stock. The offering may include an additional $52.5 million option for underwriters. The offering is subject to market conditions and no assurance can be made regarding its completion or terms. Morgan Stanley, Cowen, and SVB Securities are acting as joint book-running managers, with Baird as co-manager. The offering will be conducted under an effective shelf registration statement filed with the SEC.

Natera, Inc. (NASDAQ: NTRA) reported a strong third quarter for 2022, with total revenues of $210.6 million, up 33.2% from $158.1 million in Q3 2021. Product revenues rose 29.8% to $199.8 million. The company processed approximately 517,500 tests, an increase of 27.1%. Natera raised its revenue guidance for 2022 to $810 million - $830 million. Although net loss reduced from $151.3 million in Q3 2021 to $121.5 million, gross margin declined from 48.5% to 44.7% due to rising labor costs.

Natera, Inc. (NASDAQ: NTRA) has secured a nationwide contract with the U.S. Department of Veterans Affairs (VA) National Precision Oncology Program, effective September 15, 2022. This contract enables the provision of minimal residual disease (MRD) and monitoring services using the Signatera™ test, aimed at detecting cancer recurrence and informing treatment decisions. The VA serves over 450,000 veterans with cancer. Signatera™ is validated across multiple cancer types and is covered by Medicare for specific uses, enhancing its clinical utility and accessibility.

Natera, a leader in cell-free DNA testing, will participate in the Credit Suisse 31st Annual Healthcare Conference on November 9, 2022, at 10:25 a.m. PT. CEO Steve Chapman and CFO Mike Brophy will present at the event, highlighting Natera's advancements in personalized genetic testing. Interested parties can access the live webcast through the Natera Investor Relations website, where the presentation will also be archived for future reference.

Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA testing, will announce its third-quarter 2022 results on November 8, 2022, post-market. A conference call will follow at 1:30 p.m. PT (4:30 p.m. ET) to discuss financial outcomes, business activities, and future outlook. Investors can dial in at (888) 770-7321 for domestic or (929) 201-7107 for international access, using password 7684785. A webcast will also be available at this link. For more info on Natera, visit www.natera.com.

Natera, Inc. (NASDAQ: NTRA) announces a study published in Gynecologic Oncology, validating its molecular residual disease (MRD) test, Signatera, for epithelial ovarian cancer (EOC). The multi-site study of 163 plasma samples from 69 patients demonstrates that Signatera outperforms CA-125 in predicting recurrence. With 100% sensitivity and specificity, it detects recurrences an average of 10 months earlier than imaging. This advancement is crucial for ovarian cancer management, which has a high recurrence rate and poor survival rates.